Apella Capital LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 15,871 shares of the biopharmaceutical company’s stock, valued at approximately $582,000.
Several other large investors have also recently modified their holdings of PFE. RB Capital Management LLC increased its holdings in Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 341 shares in the last quarter. Ironwood Wealth Management LLC. grew its stake in shares of Pfizer by 1.1% during the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after purchasing an additional 400 shares during the period. United Bank grew its stake in shares of Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after purchasing an additional 290 shares during the period. Ergoteles LLC grew its stake in shares of Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp grew its stake in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after purchasing an additional 79,887 shares during the period. Hedge funds and other institutional investors own 68.05% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on PFE shares. HSBC started coverage on Pfizer in a research note on Friday, July 14th. They set a “buy” rating and a $50.00 price target for the company. BMO Capital Markets cut their price objective on Pfizer from $45.00 to $44.00 and set an “outperform” rating for the company in a research note on Wednesday, August 2nd. StockNews.com began coverage on Pfizer in a research note on Thursday, August 17th. They set a “hold” rating for the company. Barclays cut their price objective on Pfizer from $40.00 to $38.00 in a research note on Tuesday, July 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $75.00 price objective on shares of Pfizer in a research note on Tuesday, September 5th. Twelve analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $46.35.
Pfizer Stock Performance
NYSE PFE opened at $34.15 on Friday. The company has a market cap of $192.81 billion, a P/E ratio of 9.08, a P/E/G ratio of 1.14 and a beta of 0.59. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.82 and a current ratio of 2.12. The business’s 50 day moving average price is $35.86 and its 200-day moving average price is $38.06. Pfizer Inc. has a fifty-two week low of $33.54 and a fifty-two week high of $54.93.
Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.10. The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $13.36 billion. Pfizer had a return on equity of 28.36% and a net margin of 27.55%. The company’s revenue for the quarter was down 54.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.04 EPS. Sell-side analysts predict that Pfizer Inc. will post 3.33 earnings per share for the current year.
Pfizer Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th were given a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a dividend yield of 4.80%. The ex-dividend date was Thursday, July 27th. Pfizer’s dividend payout ratio is currently 43.62%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
- Five stocks we like better than Pfizer
- How to Invest in Marijuana Stocks
- 2 Wrecked Stocks Keeping Cars on the Road Ready for Repair
- Trading Stocks: RSI and Why it’s Useful
- WeWork Stock Soars: Meme Stock Madness or Mirage?
- What Are the FAANG Stocks and Are They Good Investments?
- Shutterstock is the Value Stock they don’t want you to know about
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.